Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by longrun86on Nov 11, 2021 4:49pm
220 Views
Post# 34116961

Q3 Results

Q3 ResultsAdding my two cents. I was very pleased with the Q3 results.

I thought that Q3 demonstrated excellent progress on the operations front.

I am also a shareholder in Berkshire and they always say that you can't pay too much attention to the marketable securities swings. As these investments wind down it will coincide with opportunities for Knight to deploy into operations.

In one of my previous posts I referenced that the gross margin was too low. That appears to be rectified now.

My view is that the muted market response is as a result of most people taking the day to remember. My hope is that Management remembers not to hold earnings calls again on Rememberance Day. With that said, I took the time to add some shares today at what I fell is a terrific price.
<< Previous
Bullboard Posts
Next >>